Nyrada (ASX:NYR) received approval from the Human Research Ethics Committee to start its first-in-human phase 1a clinical trial evaluating the safety, tolerability, and pharmacokinetics of drug candidate NYR-BI03, according to a Friday filing with the Australian bourse.
NYR-BI03 is a treatment that has the potential to protect both brain and heart tissue.
The double-blind, randomized, placebo-controlled study will administer either NYR-BI03 or placebo to five groups of eight healthy volunteers, with six active and two placebo participants per group, the filing said.
The first dosing is expected to begin by the end of March, according to the filing.
Nyrada's shares were up 5% in afternoon trade Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。